三阴性乳腺癌分子分型的研究进展

Research progress on molecular typing of triple-negative breast cancer

三阴性乳腺癌(TNBC)是乳腺癌的一种特殊类型,约占乳腺癌的15%~20%。因缺乏治疗靶点,TNBC的内分泌治疗和现有的靶向治疗效果欠佳,且常规化学治疗仅能使部分患者获益,是目前最具有侵略性和致命性的乳腺癌亚型。根据TNBC基因表达情况对其进一步分型可为TNBC个体化治疗的发展提供新的思路,该文就TNBC的分子分型和潜在的靶向药的最新研究进展作一介绍。

As a specific type of breast cancer,triple-negative breast cancer(TNBC) accounts for approximately 15% to 20% of breast cancer.The clinical efficacy of endocrine therapy and existing targeted interventions for TNBC is relatively low due to lack of therapeutic targets.Conventional chemotherapy merely yields clinical benefits for certain patients.Currently,TNBC is the most aggressive and lethal subtype of breast cancer.Further molecular subtyping based upon TNBC expression profiles provides novel thinkings to explore individual treatment of TNBC.Recent research progresses on the molecular subtyping and potential targeted agents of TNBC were summarized in this article.